Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad o Gontract

The Supply and Implementation of a Warehouse Management System.

  • Cyhoeddwyd gyntaf: 03 Chwefror 2017
  • Wedi'i addasu ddiwethaf: 03 Chwefror 2017

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
Cyhoeddwyd gan:
Cell & Gene Therapy Catapult
ID Awudurdod:
AA58950
Dyddiad cyhoeddi:
03 Chwefror 2017
Dyddiad Cau:
15 Chwefror 2017
Math o hysbysiad:
Hysbysiad o Gontract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

Cell and Gene Therapy Catapult (CGTC) is part of a world-leading network of technology and innovation centres, established in December 2012 and now with over 100 employees, we believe through science and industry, our expertise in cell and gene therapies will 1 day provide better treatments that will help improve patient quality of life whilst building a global industry the UK can be proud of. Our mission to deliver health and wealth is supported by the UK's enviable academic base. We strive to be a world leader in cell and gene therapy and support those who wish to convert research into products that have the potential to have direct impact in advanced healthcare.

CGTC is not alone in this ambition. Regenerative medicine is 1 of the government's eight great technologies that support UK science strengths and capabilities.

CGTC's offices are located in Guys Hospital in London. CGTC are building a 55 000 000 GBP large-scale GMP Manufacturing Centre to help bring cell and gene therapies to market in the UK and internationally. It will provide the UK with the manufacturing facilities needed for later-stage cell and gene therapy clinical studies and commercialisation. The centre benefits from an established supply chain, prime UK location in Stevenage and expert impartial advice from the Cell and Gene Therapy Catapult, enabling the manufacture of therapies to the highest grade, with minimal risk and 100 percent control.

This procurement is for the supply, implementation and support of a Warehouse Management System (WMS) for CGTC. The WMS solution will cover 2 sites, primarily the manufacturing centre in Stevenage with a subset of system functionality available for use at CGTC's Guys Hospital location. CGTC is committed to implementing an WMS system as a priority by November 2017 in time for the opening of the Manufacturing Centre. Completion of formal GMP system qualification would be required to be completed no later than November 2017 in anticipation of inspection for licensure in December 2017.

The WMS solution will include product inventory, warehousing operations and stock control management as standard functionality along with associated supporting API interfaces..

The potential budget for the WMS system is between 350 000 to 550 000 GBP total excluding VAT for the potential 5 year contract (3 years initially plus 2 further periods of up to 24 months).

Testun llawn y rhybydd

Hysbysiad contract

Adran I: Awdurdod contractio

I.1) Enw a chyfeiriad

Cell & Gene Therapy Catapult

12th Floor, Guy's Tower, Great Maze Pond

London

SE1 9RT

UK

E-bost: MCProcurement@ct.catapult.org.uk

NUTS: UKI1

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: https://ct.catapult.org.uk/

I.3) Cyfathrebu

Mae mynediad at y dogfennau caffael yn gyfyngedig. Gellir cael rhagor o wybodaeth yn:

https://ct.catapult.org.uk


Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod


Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:


I.4) Y math o awdurdod contractio

Arall: partially funded through another contracting authority

I.5) Prif weithgaredd

Arall: cell and gene therapies

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

The Supply and Implementation of a Warehouse Management System.

Cyfeirnod: CON-0082B

II.1.2) Prif god CPV

48000000

 

II.1.3) Y math o gontract

Gwasanaethau

II.1.4) Disgrifiad byr

This procurement is for the supply, implementation and support of a Warehouse Management System (WMS) for CGTC. The WMS solution will cover 2 sites, primarily the CGTC Manufacturing Centre in Stevenage with a subset of system functionality available for use at CGTC's Guys Hospital location. The system is to be supplied and implemented to CGTC's requirements by November 2017 in time for the opening of the Manufacturing Centre. Completion of formal GMP system qualification would be required to be completed no later than November 2017 in anticipation of inspection for licensure in December 2017.

II.1.5) Cyfanswm gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 550 000.00 GBP

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.2) Disgrifiad

II.2.3) Man cyflawni

Cod NUTS:

UKH23


Prif safle neu fan cyflawni:

Stevenage.

II.2.4) Disgrifiad o’r caffaeliad

Cell and Gene Therapy Catapult (CGTC) is part of a world-leading network of technology and innovation centres, established in December 2012 and now with over 100 employees, we believe through science and industry, our expertise in cell and gene therapies will 1 day provide better treatments that will help improve patient quality of life whilst building a global industry the UK can be proud of. Our mission to deliver health and wealth is supported by the UK's enviable academic base. We strive to be a world leader in cell and gene therapy and support those who wish to convert research into products that have the potential to have direct impact in advanced healthcare.

CGTC is not alone in this ambition. Regenerative medicine is 1 of the government's eight great technologies that support UK science strengths and capabilities.

CGTC's offices are located in Guys Hospital in London. CGTC are building a 55 000 000 GBP large-scale GMP Manufacturing Centre to help bring cell and gene therapies to market in the UK and internationally. It will provide the UK with the manufacturing facilities needed for later-stage cell and gene therapy clinical studies and commercialisation. The centre benefits from an established supply chain, prime UK location in Stevenage and expert impartial advice from the Cell and Gene Therapy Catapult, enabling the manufacture of therapies to the highest grade, with minimal risk and 100 percent control.

This procurement is for the supply, implementation and support of a Warehouse Management System (WMS) for CGTC. The WMS solution will cover 2 sites, primarily the manufacturing centre in Stevenage with a subset of system functionality available for use at CGTC's Guys Hospital location. CGTC is committed to implementing an WMS system as a priority by November 2017 in time for the opening of the Manufacturing Centre. Completion of formal GMP system qualification would be required to be completed no later than November 2017 in anticipation of inspection for licensure in December 2017.

The WMS solution will include product inventory, warehousing operations and stock control management as standard functionality along with associated supporting API interfaces..

The potential budget for the WMS system is between 350 000 to 550 000 GBP total excluding VAT for the potential 5 year contract (3 years initially plus 2 further periods of up to 24 months).

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 550 000.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 60

Gall y contract hwn gael ei adnewyddu: Na

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

II.2.14) Gwybodaeth ychwanegol

To express an interest to received the tender documents you must provide your contact name, position in company, company name, address, email and mobile phone contact details to MCProcurement@ct.catapult.org.uk

Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol

III.1) Amodau ar gyfer cymryd rhan

III.1.2) Statws economaidd ac ariannol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.1.3) Gallu technegol a phroffesiynol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.2) Amodau sy’n gysylltiedig â’r contract

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored - Gweithdrefn garlam

Cyfiawnhad:

This Contract Notice replaces the Contract Notice 2016/S 234-426599 published by the Catapult on 1.12.2016. That procurement was not successful to establish a successful economic operator and so the Catapult is publishing this Contract Notice with some amendments to the requirement and under an accelerated time-scale.

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

IV.2) Gwybodaeth weinyddol

IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon

Rhif yr hysbysiad yn OJ S:

2016/S 109-194128

IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law

Dyddiad: 15/02/2017

Amser lleol: 14:00

IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan

EN

IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr

Hyd mewn misoedd: 3  (o’r dyddiad a nodwyd i dendr ddod i law)

IV.2.7) Amodau ar gyfer agor tendrau

Dyddiad: 15/02/2017

Amser lleol: 14:00

Section VI: Gwybodaeth ategol

VI.1) Gwybodaeth am ailddigwydd

Caffaeliad cylchol yw hwn: Na

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

Cell & Gene Therapy Catapult

London

SE1 9RT

UK

VI.5) Dyddiad anfon yr hysbysiad hwn

27/01/2017

Codio

Categorïau nwyddau

ID Teitl Prif gategori
48000000 Systemau pecynnau meddalwedd a gwybodaeth Gwasanaethau Cyfrifiadurol a Chysylltiedig

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
MCProcurement@ct.catapult.org.uk
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.